This review provides an update on the availability and use of insulin in Aotearoa New Zealand for people with type 1 and type 2 diabetes, and other forms such as pancreatogenic diabetes. Recent changes include the funding of continuous glucose monitors and insulin pumps to allow automated insulin delivery for people with type 1 diabetes, the discontinuation of several forms of premixed insulin, and the funding of Ryzodeg, the first co-formulation of insulin analogues (70% ultralong-acting insulin degludec + 30% insulin aspart).
Please login below to download this issue (PDF)